Developing a biosimilar medicine requires significant expertise to ensure that it is “highly similar” to the reference biologic with no clinically meaningful differences in the safety profile, efficacy, or potency. This means extensively identifying and comparing the structural and functional properties of the biosimilar, using state-of-the-art technology. For a biosimilar, comparative structural and functional characterization will provide the greatest contribution to clinical predictability.

Watch this video for more information on how biosimilars are made

Transitioning to value-based care? Learn How Biosimilars may help

You are now leaving Pfizer

Link to sites outside of Pfizer are provided as a resource to the viewer. Pfizer accepts no responsibility for the content of linked sites.